Voyageur Pharmaceuticals CEO recaps milestone achievements in 2024 and outlines goals for 2025 [Video]

Voyageur Pharmaceuticals CEO Brent Willis joined Steve Darling from Proactive to share details from a recently released Letter from the CEO, highlighting the company’s significant achievements in 2024 and its ambitious plans for 2025.

Willis reflected on 2024 as a transformative year for Voyageur, with the company entering into a Letter of Intent with a large multinational pharmaceutical company. This collaboration aims to improve production efficiencies and expand Voyageur’s presence in the contrast media market. Both parties are actively working toward a definitive agreement, expected in early 2025. Voyageur introduced five new Health Canada-licensed barium contrast products aimed at raising the bar for medical imaging standards and enhancing diagnostic precision for healthcare professionals. This accomplishment followed 18 months of dedicated research and development.

The company secured a $2.7 million sales distribution contract for its SmoothX 2% Barium Contrast product, solidifying its market presence in Latin America. Regulatory approvals are in …